 Takeda Pharmaceutical Company Limited NYSE: TAK and JCR Pharmaceuticals Co Ltd have announced an exclusive collaboration and license agreement to commercialize JR-141 pabinafusp alfa for Hunter syndrome Mucopolysaccharidosis type II or MPS II. JR-141 is an investigational, next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase IDS enzyme. 